The Michael J. Fox Foundation (MJFF) is committed to sharing the risk of drug development with researchers from academia and industry alike in order to keep promising research moving forward along the Parkinson’s disease (PD) drug pipeline. To date, MJFF has funded over $300 million in research, $83 million of which has been awarded to more than 180 unique, industry-led projects. On February 20, MJFF launched nine funding programs, three of which are new to the Foundation.
Last summer, MJFF announced the launch of its newest funding mechanism, the Therapeutic Pipeline Program (TPP), an initiative for industry and academia alike seeking to support research projects at various stages throughout the drug development process. TPP’s comprehensive approach to funding encourages investigators to think holistically about the path towards therapeutic development, regardless of the current stage of their research.
TPP focuses on targets within the following specific pathways:
- Mitochondrial function
- Unfolded protein response/autophagy
- Targets involved in genetic forms of PD
To learn more about TPP, RSVP to attend an informational conference call on March 7, 2013 at 12:00 pm EST by emailing [email protected] To apply to TPP, please visit https://www.michaeljfox.org/research/grant-detail.php?id=9.
The Foundation has also launched the inaugural Synuclein Therapeutic Acceleration Program (SYNTAP), which seeks to provide funding for mid-to-late stage development of therapies targeting alpha-synuclein, a protein whose clumping in the brain is the pathological hallmark of Parkinson’s disease. SYNTAP is now accepting proposals for pre-clinical efficacy, target engagement, pharmacokinetics/pharmacodynamic evaluation, and/or safety & toxicology studies.
To learn more about SYNTAP, RSVP to attend an informational conference call on March 13, 2013 at 12:00 pm EST by emailing [email protected] To apply to SYNTAP, please visit https://www.michaeljfox.org/research/grant-detail.php?id=11.
There is currently a lot going on at MJFF, in addition to TPP and SYNTAP; researchers are invited to apply to any of nine programs that are currently open at the Foundation. On the whole, MJFF seeks projects promoting PD drug development around the most promising therapeutic pathways and targets, including two programs dedicated to leading genetic target LRRK2.
Researchers can also apply for access to MJFF’s growing inventory of tissue samples from pre-clinical models and clinical populations for projects seeking to address promising Parkinson’s ideas.
Check out the MJFF Web site for details on all nine of our current funding programs, and to apply for a grant.
We look forward to working with you as we pursue a cure for Parkinson’s.
This guest post was written by the Michael J. Fox Foundation. In addition to their funding programs, MJFF works with industry in a wide variety of ways. To learn more about these relationships, please visit their Opportunities for Industry page.